Original Post from GeneomeWeb
NEW YORK (GenomeWeb) – A team led by researchers at Baylor College of Medicine has uncovered a number of mutations in a pan-cancer analysis that it said could be used as targets for tailored treatments.
Using data from the Cancer Genome Atlas, the researchers examined molecular alterations affecting the PI3K/AKT/mTOR pathway in more than 11,000 cancers from 32 tumor types. The PI3K/AKT/mTOR pathway is a growth regulatory pathway that is often activated in cancer.
As the team reported yesterday in Cancer Cell, it used whole-genome sequencing, whole-exome sequencing, copy number, and proteomic data from TCGA to home in on molecular changes affecting the PI3K/AKT/mTOR pathway that are likely functional.
“PI3K is the most commonly mutated pathway in cancer that can be targeted by drugs,” coauthor Gordon Mills, professor of medicine and immunology at MD Anderson Cancer Center, said in a statement. “Thus, understanding how the pathway and mutations in cancer affect the many different cancer lineages is important.”
The researchers gathered 11,219 human cancer cases — representing 32 major types of cancer — for which the TCGA had generated data using one or more molecular approaches.
The proteomic data gathered via reverse-phase protein arrays covered more than 7,600 samples from